According to Securities Star News, as of the close of trading on May 17, 2024, Oriental Biotechnology (688298) closed at 30.17 yuan, down 1.41%, with a turnover rate of 0.91%, a volume of 18,400 contracts and a turnover of 55.4543 million yuan.
In terms of capital flow data on May 17, the net inflow of main funds was 3.1146 million yuan, accounting for 5.62% of the total turnover, the net outflow of floating funds was 3.5727 million yuan, accounting for 6.44% of the total turnover, and the net inflow of retail funds was 458,000 yuan, accounting for 0.83% of the total turnover.
The list of capital flows in the past 5 days is shown in the following table:
According to the financing information of Oriental Biologics, in terms of financing, the financing purchase on the same day was 4.6192 million yuan, the financing repayment was 2.3604 million yuan, and the financing net purchase was 2.2588 million yuan. In terms of securities lending, 1,800.0 shares were sold by securities borrowing, 7,297.0 shares were repaid by securities borrowing, 232,500 shares were borrowed and borrowed, and the balance of securities borrowing and lending was 7,014,200 yuan. The balance of margin financing and securities lending was 274 million yuan. See the following table for a list of margin trading data in the past 5 days:
The main indicators and industry rankings of the stock are as follows:
Dongfang Biotech's 2024 first quarter report shows that the company's main revenue was 183 million yuan, a year-on-year decrease of 51.36%; net profit attributable to the parent company -67.3535 million yuan, a year-on-year decrease of 33.82%; deducted non-net profit of -109 million yuan, a year-on-year decrease of 281.26%; The debt ratio was 13.96%, the investment income was 15.2783 million yuan, the financial expenses were -35.0936 million yuan, and the gross profit margin was 32.35%. Dongfang Biotech (688298) main business: specializing in the research and development, production and sales of in vitro diagnostic products, forming a business pattern with POCT point-of-care diagnostic reagents as the leading products, focusing on the development of molecular diagnostics, biological raw materials, diagnostic instruments and liquid biochips and other products.
Explanation of the term capital flow: It refers to the reversal of the flow of funds through price changes. When the stock price is rising, the turnover generated by the active buy order is the force that drives the stock price up, which is defined as the inflow of funds, and the turnover generated by the active sell order when the stock price is in a falling state is the force that pushes the stock price down, and this part of the turnover is defined as the outflow of funds. The difference between the two on the day is the net force that is left to push the stock price up after the two forces offset on that day. The main capital flow, floating capital flow and retail capital flow are calculated by the transaction amount of each transaction order.
Note: The main funds are extra-large single transactions, the floating capital is large single transactions, and the retail investors are small and medium-sized single transactions
The above content is compiled by Securities Star based on public information, generated by an algorithm (Network Information Calculation No. 310104345710301240019), and has nothing to do with the position of this site, if there is a problem with the data, please contact us. This article is a compilation of data and does not constitute any investment advice for you, investment is risky, please make a cautious decision.